| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005784241 |
| P356 | DOI | 10.1038/NRN3880 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nrn3880 |
| P8608 | Fatcat ID | release_aethxgergrdbtgmiemu6luifsq |
| P698 | PubMed publication ID | 25991443 |
| P50 | author | Frank L. Heppner | Q56955724 |
| Richard M Ransohoff | Q87833085 | ||
| Burkhard Becher | Q48129628 | ||
| P2860 | cites work | Microglia as dynamic and essential components of the amyloid hypothesis. | Q50952172 |
| Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". | Q50963355 | ||
| Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death. | Q51029020 | ||
| Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. | Q51867743 | ||
| A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. | Q53228560 | ||
| Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. | Q53338394 | ||
| Interleukin-23 receptor polymorphisms are associated with Alzheimer's disease in Han Chinese. | Q53351175 | ||
| Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models | Q57149911 | ||
| Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease | Q57782086 | ||
| Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease | Q73066482 | ||
| Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease? | Q77497782 | ||
| Animal models of multiple sclerosis: the good, the bad and the bottom line | Q84632736 | ||
| Emerging therapeutics for Alzheimer's disease | Q87039918 | ||
| Alzheimer's Disease | Q22248111 | ||
| TREM2 Variants in Alzheimer's Disease | Q22250873 | ||
| Variant of TREM2 Associated with the Risk of Alzheimer's Disease | Q22250874 | ||
| A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline | Q22251083 | ||
| The ageing systemic milieu negatively regulates neurogenesis and cognitive function. | Q24599219 | ||
| NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice | Q24604235 | ||
| Long-term cognitive impairment and functional disability among survivors of severe sepsis | Q24628579 | ||
| ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models | Q24628845 | ||
| Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis | Q24635370 | ||
| CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer | Q24642646 | ||
| Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease | Q24803797 | ||
| Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP[V717I] transgenic mice | Q24812365 | ||
| Transcription factors and CD4 T cells seeking identity: masters, minions, setters and spikers | Q26859465 | ||
| Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology | Q27327835 | ||
| Astrocytes: biology and pathology | Q27490746 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide | Q28131750 | ||
| Inflammation and Alzheimer's disease | Q28138617 | ||
| M-1/M-2 macrophages and the Th1/Th2 paradigm | Q28145893 | ||
| Trafficking and proteolytic processing of APP | Q28265871 | ||
| Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner | Q28267444 | ||
| The complement system: an unexpected role in synaptic pruning during development and disease | Q28269217 | ||
| A meta-analysis of cytokines in Alzheimer's disease | Q28289922 | ||
| TREM2 and the neuroimmunology of Alzheimer's disease | Q28304401 | ||
| Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease | Q36726269 | ||
| Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease | Q36771851 | ||
| Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice | Q36817659 | ||
| The role of microglia in amyloid clearance from the AD brain | Q36841789 | ||
| Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease | Q36914722 | ||
| Scara1 deficiency impairs clearance of soluble amyloid-β by mononuclear phagocytes and accelerates Alzheimer's-like disease progression | Q36985041 | ||
| CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology | Q36990425 | ||
| Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta | Q36996975 | ||
| Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice | Q37003128 | ||
| Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes | Q37012919 | ||
| Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease | Q37078772 | ||
| Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. | Q37079075 | ||
| Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients | Q37102841 | ||
| Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology | Q37113528 | ||
| The effects of aging, injury and disease on microglial function: a case for cellular senescence | Q37219001 | ||
| CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. | Q37230760 | ||
| Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. | Q37287738 | ||
| The microglial sensome revealed by direct RNA sequencing | Q37341692 | ||
| Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation | Q37395599 | ||
| Quantitative and mechanistic studies of Abeta immunotherapy | Q37411413 | ||
| CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. | Q37424811 | ||
| Microglia in neurodegenerative disease | Q37710380 | ||
| Alzheimer's disease: strategies for disease modification | Q37739810 | ||
| Systemic inflammatory cells fight off neurodegenerative disease | Q37763505 | ||
| Contribution of systemic inflammation to chronic neurodegeneration | Q37774280 | ||
| Heterogeneity of CNS myeloid cells and their roles in neurodegeneration | Q37939514 | ||
| Helper T-cell differentiation and plasticity: insights from epigenetics. | Q37942972 | ||
| Transcriptional regulation of macrophage polarization: enabling diversity with identity | Q37949245 | ||
| Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature | Q37982377 | ||
| Mast cells: an expanding pathophysiological role from allergy to other disorders | Q38007884 | ||
| Functions of microglia in the central nervous system--beyond the immune response. | Q38011858 | ||
| Microglia and neurodegeneration: the role of systemic inflammation. | Q38016812 | ||
| Proteolytic degradation of amyloid β-protein | Q38016899 | ||
| Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where | Q38021993 | ||
| Neurotoxicity of amyloid β-protein: synaptic and network dysfunction | Q38023860 | ||
| Animal models of Alzheimer disease | Q38045853 | ||
| Deciphering the mechanism underlying late-onset Alzheimer disease | Q38062817 | ||
| Regulators of chromatin state and transcription in CD4 T-cell polarization | Q38099414 | ||
| Alzheimer disease therapy--moving from amyloid-β to tau. | Q38161786 | ||
| Dystrophic microglia in the aging human brain | Q48090856 | ||
| Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial | Q48187875 | ||
| Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease | Q48247414 | ||
| PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. | Q48273067 | ||
| Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. | Q48281683 | ||
| Focal demyelination in Alzheimer's disease and transgenic mouse models. | Q48285985 | ||
| Expression of complement messenger RNAs and proteins by human oligodendroglial cells. | Q48317953 | ||
| Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. | Q48337623 | ||
| Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. | Q48369444 | ||
| Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. | Q48456362 | ||
| Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. | Q48459353 | ||
| Neuroinflammatory cytokine signaling and Alzheimer's disease. | Q48514196 | ||
| Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. | Q48933977 | ||
| Multiple cellular and molecular mechanisms are involved in human Aβ clearance by transplanted adult astrocytes. | Q48957718 | ||
| Complement-activated oligodendroglia: a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d. | Q48973640 | ||
| Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. | Q50746555 | ||
| Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice | Q28345644 | ||
| CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation | Q28506984 | ||
| Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia | Q28573077 | ||
| Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease | Q28943325 | ||
| Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models" | Q29013008 | ||
| Comment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models" | Q29543792 | ||
| Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease | Q29614374 | ||
| Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease | Q29614879 | ||
| Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease | Q29614881 | ||
| Synaptic pruning by microglia is necessary for normal brain development | Q29615591 | ||
| The NALP3 inflammasome is involved in the innate immune response to amyloid-beta | Q29615595 | ||
| The M1 and M2 paradigm of macrophage activation: time for reassessment | Q29615845 | ||
| Decreased clearance of CNS beta-amyloid in Alzheimer's disease | Q29616534 | ||
| Macrophage activation and polarization: nomenclature and experimental guidelines | Q29620642 | ||
| Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration | Q30481096 | ||
| Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy | Q30499456 | ||
| Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice | Q30527791 | ||
| Microglial beclin 1 regulates retromer trafficking and phagocytosis and is impaired in Alzheimer's disease | Q30545790 | ||
| Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease | Q30581719 | ||
| Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice. | Q30597164 | ||
| TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice | Q33343490 | ||
| An immunofluorescence method for postembedded tissue in the acrylic resin Technovit 9100 New using fluorescein isothiocyanate secondary detection. | Q33419956 | ||
| Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. | Q33662701 | ||
| Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2. | Q33727947 | ||
| Systemic inflammation and disease progression in Alzheimer disease | Q33765718 | ||
| Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes | Q33859600 | ||
| Identification of a CD20-, FcepsilonRIbeta-, and HTm4-related gene family: sixteen new MS4A family members expressed in human and mouse | Q33950856 | ||
| Soluble Aβ oligomers are rapidly sequestered from brain ISF in vivo and bind GM1 ganglioside on cellular membranes | Q34031193 | ||
| Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo | Q34049368 | ||
| Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice | Q34076162 | ||
| Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib | Q34077849 | ||
| Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. | Q34253312 | ||
| CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. | Q34254575 | ||
| Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview | Q34277859 | ||
| Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease | Q34309107 | ||
| Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. | Q34490657 | ||
| Microglia actions in Alzheimer’s disease. | Q38162232 | ||
| Molecular links between endothelial dysfunction and neurodegeneration in Alzheimer's disease. | Q38164018 | ||
| Reactive gliosis and the multicellular response to CNS damage and disease. | Q38181737 | ||
| Microglial priming in neurodegenerative disease | Q38196699 | ||
| Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease | Q38203104 | ||
| Innate immune activation in neurodegenerative disease | Q38223011 | ||
| Sublime microglia: expanding roles for the guardians of the CNS. | Q38226364 | ||
| Age-dependent decrease in glutamine synthetase expression in the hippocampal astroglia of the triple transgenic Alzheimer's disease mouse model: mechanism for deficient glutamatergic transmission? | Q38801058 | ||
| TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis | Q38978510 | ||
| Parallel discovery of Alzheimer's therapeutics | Q39173518 | ||
| Endothelin-1 is elevated in Alzheimer's disease and upregulated by amyloid-β. | Q39397123 | ||
| In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3β and secretases. | Q39448933 | ||
| Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta | Q39875838 | ||
| AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice | Q39893541 | ||
| Microglial phagocytosis of fibrillar beta-amyloid through a beta1 integrin-dependent mechanism. | Q40496060 | ||
| A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. | Q40657503 | ||
| Up-regulation of FPR2, a chemotactic receptor for amyloid beta 1-42 (A beta 42), in murine microglial cells by TNF alpha | Q40701969 | ||
| Elevated circulating tumor necrosis factor levels in Alzheimer's disease | Q41145103 | ||
| Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils | Q41173971 | ||
| Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease | Q41753192 | ||
| A limited role for microglia in antibody mediated plaque clearance in APP mice | Q41886581 | ||
| Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice | Q42001466 | ||
| IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. | Q42174144 | ||
| Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice | Q42243192 | ||
| Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. | Q42352469 | ||
| Peripheral inflammatory cytokines as biomarkers in Alzheimer's disease and mild cognitive impairment | Q42520156 | ||
| CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. | Q42709761 | ||
| A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia | Q42726693 | ||
| IL12/23 p40 inhibition ameliorates Alzheimer's disease-associated neuropathology and spatial memory in SAMP8 mice | Q43682499 | ||
| Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. | Q43882557 | ||
| Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. | Q44241464 | ||
| Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains | Q44410484 | ||
| Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation | Q44433388 | ||
| Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial | Q44463935 | ||
| Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration | Q44748602 | ||
| Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". | Q45080391 | ||
| Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling | Q45186177 | ||
| TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. | Q45972218 | ||
| Block of purinergic P2X(7) receptor is neuroprotective in an animal model of Alzheimer's disease | Q46318483 | ||
| Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. | Q46389933 | ||
| Amyloid beta peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures | Q46584409 | ||
| Transforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies. | Q46609616 | ||
| Adult mouse astrocytes degrade amyloid-beta in vitro and in situ | Q46779933 | ||
| Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease | Q46942969 | ||
| Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. | Q47230871 | ||
| Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides | Q47349499 | ||
| The LPS receptor (CD14) links innate immunity with Alzheimer's disease | Q47405789 | ||
| SnapShot: pathobiology of Alzheimer's disease | Q47975976 | ||
| Hippocampal expression of murine TNFα results in attenuation of amyloid deposition in vivo | Q34633199 | ||
| Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. | Q34656871 | ||
| Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. | Q34659689 | ||
| Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community-dwelling elderly persons and their first-degree relatives | Q34662741 | ||
| Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox | Q34685501 | ||
| A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model | Q34746889 | ||
| Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease | Q34774194 | ||
| Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial | Q34798154 | ||
| Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition | Q34878224 | ||
| Neuroinflammation in Alzheimer's disease and prion disease. | Q34963776 | ||
| Differential role of CCR2 in the dynamics of microglia and perivascular macrophages during prion disease | Q35071802 | ||
| Extended results of the Alzheimer's disease anti-inflammatory prevention trial | Q35146385 | ||
| TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. | Q35161472 | ||
| The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease | Q35172428 | ||
| Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. | Q35231254 | ||
| A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. | Q35350543 | ||
| Intrathecal inflammation precedes development of Alzheimer's disease | Q35476365 | ||
| Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial | Q35579238 | ||
| Obesity is associated with hypothalamic injury in rodents and humans | Q35640638 | ||
| TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model | Q35771760 | ||
| Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease | Q35782497 | ||
| Microglia and Alzheimer's disease pathogenesis | Q35805628 | ||
| Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study | Q36164195 | ||
| Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease | Q36183810 | ||
| Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation | Q36231523 | ||
| Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition | Q36232140 | ||
| Cellular resistance to infection | Q36265994 | ||
| Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease | Q36330297 | ||
| Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity | Q36348121 | ||
| CD36 mediates the innate host response to beta-amyloid | Q36370903 | ||
| Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia | Q36487090 | ||
| Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype | Q36503998 | ||
| Neuroinflammatory phenotype in early Alzheimer's disease | Q36629135 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| Alzheimer's disease | Q11081 | ||
| P304 | page(s) | 358-372 | |
| P577 | publication date | 2015-06-01 | |
| P1433 | published in | Nature Reviews Neuroscience | Q2108225 |
| P1476 | title | Immune attack: the role of inflammation in Alzheimer disease | |
| P478 | volume | 16 |
| Q64076394 | (5R)-5-hydroxytriptolide inhibits the inflammatory cascade reaction in astrocytes |
| Q95839898 | A 3'UTR modification of the TNF-α mouse gene increases peripheral TNF-α and modulates the Alzheimer-like phenotype in 5XFAD mice |
| Q39266481 | A New Treatment Strategy for Parkinson's Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway |
| Q51786227 | A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. |
| Q90654725 | A Novel scFv Anti-Aβ Antibody Reduces Pathological Impairments in APP/PS1 Transgenic Mice via Modulation of Inflammatory Cytokines and Aβ-related Enzymes |
| Q91973479 | A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease |
| Q92932610 | A Small Compound Targeting Prohibitin with Potential Interest for Cognitive Deficit Rescue in Aging mice and Tau Pathology Treatment |
| Q91994502 | A Standardized Extract of Asparagus officinalis Stem (ETAS®) Ameliorates Cognitive Impairment, Inhibits Amyloid β Deposition via BACE-1 and Normalizes Circadian Rhythm Signaling via MT1 and MT2 |
| Q38672340 | A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease |
| Q46260569 | A critical role of TRPM2 channel in Aβ42 -induced microglial activation and generation of tumor necrosis factor-α. |
| Q54959405 | A guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models. |
| Q57804842 | A histone acetylome-wide association study of Alzheimer's disease identifies disease-associated H3K27ac differences in the entorhinal cortex |
| Q90375051 | A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain |
| Q90084122 | A novel kit for early diagnosis of Alzheimer's disease using a fluorescent nanoparticle imaging |
| Q42363726 | A roadmap for investigating the role of the prion protein in depression associated with neurodegenerative disease |
| Q92441818 | A serum protein signature of APOE genotypes in centenarians |
| Q33837684 | A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation |
| Q36925910 | AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer's Disease |
| Q91614776 | APOE ε4-specific associations of VEGF gene family expression with cognitive aging and Alzheimer's disease |
| Q53581570 | APP Modulates Aβ-Induced Activation of Microglia in Mouse Model of Alzheimer's Disease. |
| Q89877520 | AVNP2 protects against cognitive impairments induced by C6 glioma by suppressing tumour associated inflammation in rats |
| Q90679887 | Adult Goat Retinal Neuronal Culture: Applications in Modeling Hyperglycemia |
| Q37147054 | Aging Shapes the Population-Mean and -Dispersion of Gene Expression in Human Brains |
| Q64885202 | Aging and Alzheimer's disease: Comparison and associations from molecular to system level. |
| Q91878545 | Ajudecumin A from Ajuga ovalifolia var. calantha exhibits anti-inflammatory activity in lipopolysaccharide-activated RAW264.7 murine macrophages and animal models of acute inflammation |
| Q39028577 | Alcohol and Alzheimer's Disease-Does Alcohol Dependence Contribute to Beta-Amyloid Deposition, Neuroinflammation and Neurodegeneration in Alzheimer's Disease? |
| Q90324488 | All Trans Retinoic Acid Attenuates Markers of Neuroinflammation in Rat Brain by Modulation of SIRT1 and NFκB |
| Q37457369 | Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities |
| Q47095504 | Alzheimer's disease and cigarette smoke components: effects of nicotine, PAHs, and Cd(II), Cr(III), Pb(II), Pb(IV) ions on amyloid-β peptide aggregation |
| Q47700520 | Alzheimer's disease and cytokine IL-10 gene polymorphisms: is there an association? |
| Q99545663 | Alzheimer's disease: natural products as inhibitors of neuroinflammation |
| Q96230867 | Alzheimer's-associated PLCγ2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia |
| Q47157679 | Ameliorating Amyloid-β Fibrils Triggered Inflammation via Curcumin-Loaded Polymeric Nanoconstructs |
| Q39385143 | Amyloid plaques beyond Aβ: a survey of the diverse modulators of amyloid aggregation |
| Q37721846 | An Extract from Shrimp Processing By-Products Protects SH-SY5Y Cells from Neurotoxicity Induced by Aβ25-35. |
| Q58202794 | An isoform-selective p38α mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer's disease |
| Q90280217 | Analysis of Surface Levels of IL-1 Receptors and Macrophage Scavenger Receptor I in Peripheral Immune Cells of Patients With Alzheimer Disease |
| Q40086374 | Analyzing Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activation in Aging and Vascular Amyloid Pathology. |
| Q28073444 | Anti-Inflammatory Activity of Natural Products |
| Q55560479 | Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights. |
| Q30390299 | Anti-Viral Properties of Amyloid-β Peptides |
| Q59129999 | Anti-inflammatory Effects of Homotaurine in Patients With Amnestic Mild Cognitive Impairment |
| Q47230749 | Anti-inflammatory effect and mechanism of the spirocyclopiperazinium salt compound LXM-15 in rats and mice |
| Q92066018 | Anti-interleukin-17A and anti-interleukin-23 antibodies may be effective against Alzheimer's disease: Role of neutrophils in the pathogenesis |
| Q42292247 | Antiaging and Anxiolytic Effects of Combinatory Formulas Based on Four Medicinal Herbs. |
| Q39037584 | ApoE, ApoE Receptors, and the Synapse in Alzheimer's Disease |
| Q89391648 | Aspirin Induces Lysosomal Biogenesis and Attenuates Amyloid Plaque Pathology in a Mouse Model of Alzheimer's Disease via PPARα |
| Q37286244 | Assessing the Effects of Acute Amyloid β Oligomer Exposure in the Rat. |
| Q37220627 | Assessment of neuroinflammation in a mouse model of obesity and β-amyloidosis using PET. |
| Q36999150 | Association Between Genetic Traits for Immune-Mediated Diseases and Alzheimer Disease |
| Q50026626 | Association of 10-year C-reactive protein trajectories with markers of healthy aging: findings from the English Longitudinal Study of Ageing. |
| Q37015189 | Association of Serum Vitamin D with the Risk of Incident Dementia and Subclinical Indices of Brain Aging: The Framingham Heart Study |
| Q38672291 | Association of amine biomarkers with incident dementia and Alzheimer's disease in the Framingham Study |
| Q98204288 | Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions |
| Q41634210 | Association of interleukin-33 gene polymorphisms with susceptibility to late onset Alzheimer's disease: a meta-analysis |
| Q99585388 | Association of neuroinflammation with episodic memory: a [11C]PBR28 PET study in cognitively discordant twin pairs |
| Q64927642 | Association of plasma endothelial lipase levels on cognitive impairment. |
| Q90436647 | Astrocytes and microglia: Models and tools |
| Q90183678 | Astrocytes in chronic pain and itch |
| Q39253339 | Atypical microglial response to biodiesel exhaust in healthy and hypertensive rats. |
| Q26779681 | Aβ Clearance, "hub" of Multiple Deficiencies Leading to Alzheimer Disease |
| Q91236273 | B cells in autoimmune and neurodegenerative central nervous system diseases |
| Q92294587 | BAP31 regulates IRAK1-dependent neuroinflammation in microglia |
| Q91992233 | BDNF-producing, amyloid β-specific CD4 T cells as targeted drug-delivery vehicles in Alzheimer's disease |
| Q87754594 | Bayesian Cox Proportional Hazards Model in Survival Analysis of HACE1 Gene with Age at Onset of Alzheimer's Disease |
| Q90581071 | Bee venom phospholipase A2 ameliorates amyloidogenesis and neuroinflammation through inhibition of signal transducer and activator of transcription-3 pathway in Tg2576 mice |
| Q37270852 | Behavioral and omics analyses study on potential involvement of dipeptide balenine through supplementation in diet of senescence-accelerated mouse prone 8. |
| Q99635814 | Benzo(a)pyrene exposure induced neuronal loss, plaque deposition, and cognitive decline in APP/PS1 mice |
| Q64018601 | Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. |
| Q41217789 | Brain omega-3 polyunsaturated fatty acids modulate microglia cell number and morphology in response to intracerebroventricular amyloid-β 1-40 in mice. |
| Q52571424 | Brain-Resident Microglia and Blood-Borne Macrophages Orchestrate Central Nervous System Inflammation in Neurodegenerative Disorders and Brain Cancer. |
| Q38760659 | CD44 Splice Variants as Potential Players in Alzheimer's Disease Pathology |
| Q51007088 | Cardiac fibroblast cytokine profiles induced by proinflammatory or profibrotic stimuli promote monocyte recruitment and modulate macrophage M1/M2 balance in vitro. |
| Q58698909 | Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse model |
| Q50034510 | Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage. |
| Q36439886 | Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease |
| Q57493750 | Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer's disease |
| Q52839352 | Changes in Plasma β-NGF and Its Receptors Expression on Peripheral Blood Monocytes During Alzheimer's Disease Progression. |
| Q64779737 | Characteristics and advantages of adeno-associated virus vector-mediated gene therapy for neurodegenerative diseases |
| Q90425577 | Chemical Space and Biological Target Network of Anti-Inflammatory Natural Products |
| Q33751386 | Chemical probes targeting epigenetic proteins: Applications beyond oncology |
| Q50472663 | Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AβPPswe/PSEN1dE9 Alzheimer's Disease Model Mice Fed a High-Fat Diet. |
| Q36691483 | Chronic Toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes. |
| Q47582552 | Chronic inflammation - inflammaging - in the ageing cochlea: A novel target for future presbycusis therapy. |
| Q90251670 | Chronic sleep fragmentation shares similar pathogenesis with neurodegenerative diseases: Endosome-autophagosome-lysosome pathway dysfunction and microglia-mediated neuroinflammation |
| Q55505826 | Chronic stress as a risk factor for Alzheimer's disease: Roles of microglia-mediated synaptic remodeling, inflammation, and oxidative stress. |
| Q90714617 | Cinnamic acid activates PPARα to stimulate Lysosomal biogenesis and lower Amyloid plaque pathology in an Alzheimer's disease mouse model |
| Q64882308 | Circadian Rhythm and Alzheimer's Disease. |
| Q58301002 | Circulating, Cell-Free Micro-RNA Profiles Reflect Discordant Development of Dementia in Monozygotic Twins |
| Q38761126 | Clinical and Environmental Correlates of Serum BDNF: A Descriptive Study with Plausible Implications for AD Research |
| Q37054001 | Cognitive Stimulation Modulates Platelet Total Phospholipases A2 Activity in Subjects with Mild Cognitive Impairment |
| Q46463478 | Combinatorial Treatment Effects in a Cell Culture Model of Alzheimer's Disease. |
| Q37559815 | Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease |
| Q47105056 | Comparative profiling of cortical gene expression in Alzheimer's disease patients and mouse models demonstrates a link between amyloidosis and neuroinflammation |
| Q39447009 | Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease |
| Q37248499 | Complement-Mediated Regulation of Metabolism and Basic Cellular Processes |
| Q52315330 | Complex role of chemokine mediators in animal models of Alzheimer's Disease. |
| Q60923543 | Condition-specific gene co-expression network mining identifies key pathways and regulators in the brain tissue of Alzheimer's disease patients |
| Q47651485 | Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases |
| Q59791994 | Contribution of Neurons and Glial Cells to Complement-Mediated Synapse Removal during Development, Aging and in Alzheimer's Disease |
| Q42085409 | Copper Exposure Perturbs Brain Inflammatory Responses and Impairs Clearance of Amyloid-Beta |
| Q38763060 | Copper, differently from zinc, affects the conformation, oligomerization state and activity of bradykinin. |
| Q47349501 | Correcting miR92a-vGAT-Mediated GABAergic Dysfunctions Rescues Human Tau-Induced Anxiety in Mice |
| Q36048502 | Correlative Light and Electron Microscopy to Study Microglial Interactions with β-Amyloid Plaques |
| Q26799411 | Coupled cell networks are target cells of inflammation, which can spread between different body organs and develop into systemic chronic inflammation |
| Q48192562 | Crocus sativus Extract Tightens the Blood-Brain Barrier, Reduces Amyloid β Load and Related Toxicity in 5XFAD Mice. |
| Q89497672 | Culprit or Bystander: Defective Mitophagy in Alzheimer's Disease |
| Q54968424 | Curcumin Treatment is Associated with Increased Expression of the N-Methyl-D-Aspartate Receptor (NMDAR) Subunit, NR2A, in a Rat PC12 Cell Line Model of Alzheimer's Disease Treated with the Acetyl Amyloid-β Peptide, Aβ(25-35). |
| Q52689556 | Curcuminoid submicron particle ameliorates cognitive deficits and decreases amyloid pathology in Alzheimer's disease mouse model. |
| Q48153970 | Cyclodextrins 3-Functionalized with 8-Hydroxyquinolines: Copper-Binding Ability and Inhibition of Synuclein Aggregation |
| Q39029104 | Cytokine networks in neuroinflammation |
| Q59128496 | Cytokine profiles and diagnoses in elderly, hospitalized psychiatric patients |
| Q39220104 | Cytokines and cytokine networks target neurons to modulate long-term potentiation |
| Q42094554 | Dark microglia: A new phenotype predominantly associated with pathological states. |
| Q64093643 | Data-Driven Analysis of Age, Sex, and Tissue Effects on Gene Expression Variability in Alzheimer's Disease |
| Q55517504 | Death-associated protein kinase 1 mediates interleukin-1β production through regulating inlfammasome activation in Bv2 microglial cells and mice. |
| Q48630247 | Deep Brain Stimulation of the Fornix: Engaging Therapeutic Circuits and Networks in Alzheimer Disease. |
| Q58698087 | Deficient Wnt Signaling and Synaptic Vulnerability in Alzheimer’s Disease: Emerging Roles for the LRP6 Receptor |
| Q37694473 | Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms. |
| Q89285825 | Dendritic Cells as an Alternate Approach for Treatment of Neurodegenerative Disorders |
| Q42368761 | Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach |
| Q57030267 | Development of a Human APOE Knock-in Mouse Model for Study of Cognitive Function After Cancer Chemotherapy |
| Q38915171 | Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases |
| Q92193185 | Diet Associated with Inflammation and Alzheimer's Disease |
| Q64075735 | Diet and Inflammation in Cognitive Ageing and Alzheimer's Disease |
| Q47429414 | Dietary fish oil, and to a lesser extent the fat-1 transgene, increases astrocyte activation in response to intracerebroventricular amyloid-β 1-40 in mice |
| Q89578540 | Different Effects of Nicotine and N-Stearoyl-ethanolamine on Episodic Memory and Brain Mitochondria of α7 Nicotinic Acetylcholine Receptor Knockout Mice |
| Q59335552 | Different Patterns of Neurodegeneration and Glia Activation in CA1 and CA3 Hippocampal Regions of TgCRND8 Mice |
| Q41887011 | Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia |
| Q58794404 | Differential chemokine expression under the control of peripheral blood mononuclear cells issued from Alzheimer's patients in a human blood brain barrier model |
| Q48141250 | Differential contribution of microglia and monocytes in neurodegenerative diseases. |
| Q40240888 | Direct Evidence of Internalization of Tau by Microglia In Vitro and In Vivo. |
| Q36329594 | Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease |
| Q59328931 | Distinct Microglial Responses in Two Transgenic Murine Models of TAU Pathology |
| Q90573489 | Divergent roles of astrocytic versus neuronal EAAT2 deficiency on cognition and overlap with aging and Alzheimer's molecular signatures |
| Q59128213 | Diverse Protein Profiles in CNS Myeloid Cells and CNS Tissue From Lipopolysaccharide- and Vehicle-Injected APP/PS1 Transgenic Mice Implicate Cathepsin Z in Alzheimer's Disease |
| Q89855148 | Drug Development for Central Nervous System Diseases Using In Vitro Blood-brain Barrier Models and Drug Repositioning |
| Q39217121 | Dynamics of the Complement, Cytokine, and Chemokine Systems in the Regulation of Synaptic Function and Dysfunction Relevant to Alzheimer's Disease |
| Q90072371 | Dysregulated Gut Homeostasis Observed Prior to the Accumulation of the Brain Amyloid-β in Tg2576 Mice |
| Q50420748 | Dysregulation of the epigenetic landscape of normal aging in Alzheimer's disease. |
| Q58549216 | Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review |
| Q36265825 | Early astrocytosis in autosomal dominant Alzheimer's disease measured in vivo by multi-tracer positron emission tomography |
| Q38676509 | Early-Life Toxic Insults and Onset of Sporadic Neurodegenerative Diseases-an Overview of Experimental Studies |
| Q38734833 | Effective expression of Drebrin in hippocampus improves cognitive function and alleviates lesions of Alzheimer's disease in APP (swe)/PS1 (ΔE9) mice. |
| Q61811616 | Effects of BIS-MEP on Reversing Amyloid Plaque Deposition and Spatial Learning and Memory Impairments in a Mouse Model of β-Amyloid Peptide- and Ibotenic Acid-Induced Alzheimer's Disease |
| Q46022682 | Effects of HLA-DRB1/DQB1 Genetic Variants on Neuroimaging in Healthy, Mild Cognitive Impairment, and Alzheimer's Disease Cohorts. |
| Q48059413 | Effects of interleukin-1ß on cortical spreading depolarization and cerebral vasculature |
| Q90680244 | Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice |
| Q50852421 | Efficient synthesis of longer Aβ peptides via removable backbone modification. |
| Q58751451 | Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO |
| Q26769059 | Emerging Roles of Filopodia and Dendritic Spines in Motoneuron Plasticity during Development and Disease |
| Q36643093 | Endothelial Dysfunction and Amyloid-β-Induced Neurovascular Alterations. |
| Q92581386 | Endothelial Immune Activation by Medin: Potential Role in Cerebrovascular Disease and Reversal by Monosialoganglioside-Containing Nanoliposomes |
| Q92856694 | Entanglement of CCR5 and Alzheimer's Disease |
| Q37638090 | Entorhinal Cortex dysfunction can be rescued by inhibition of microglial RAGE in an Alzheimer's disease mouse model |
| Q103803412 | Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer's disease |
| Q38838452 | Estrogens, Neuroinflammation, and Neurodegeneration. |
| Q39428145 | Evaluation of dietary and lifestyle changes as modifiers of S100β levels in Alzheimer's disease. |
| Q47766786 | Examining the Role of Microglia and Astroglia During the Pathogenesis of Alzheimer's Disease via the Puri-Li Model. |
| Q60045416 | Exercise-Induced Modulation of Neuroinflammation in Models of Alzheimer's Disease |
| Q64072899 | Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease |
| Q26750366 | Exploring the Homeostatic and Sensory Roles of the Immune System |
| Q91583516 | Exploring the Role of P2X Receptors in Alzheimer's Disease |
| Q90574605 | Exposure to Ambient Air Pollution and Cognitive Impairment in Community-Dwelling Older Adults: The Korean Frailty and Aging Cohort Study |
| Q38888419 | Fas apoptosis inhibitory molecules: more than death-receptor antagonists in the nervous system |
| Q57464776 | Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration |
| Q30764311 | Formyl-Peptide Receptor 2/3/Lipoxin A4 Receptor Regulates Neutrophil-Platelet Aggregation and Attenuates Cerebral Inflammation: Impact for Therapy in Cardiovascular Disease |
| Q92912277 | Frailty effects on non-demented cognitive trajectories are moderated by sex and Alzheimer's genetic risk |
| Q28077869 | Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging |
| Q92535560 | Friend, Foe or Both? Immune Activity in Alzheimer's Disease |
| Q38608481 | From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation |
| Q48159157 | From peroxisomal disorders to common neurodegenerative diseases - the role of ether phospholipids in the nervous system. |
| Q57174266 | Functional neuroanatomy of peripheral inflammatory physiology: A meta-analysis of human neuroimaging studies |
| Q42373554 | Gad67 haploinsufficiency reduces amyloid pathology and rescues olfactory memory deficits in a mouse model of Alzheimer's disease |
| Q93152973 | Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimer's Disease via Peroxisome Proliferator-Activated Receptor α |
| Q46113901 | Genetic Association of HLA Gene Variants with MRI Brain Structure in Alzheimer's Disease |
| Q38616054 | Genetic Deletion of Tumor Necrosis Factor-α Attenuates Amyloid-β Production and Decreases Amyloid Plaque Formation and Glial Response in the 5XFAD Model of Alzheimer's Disease |
| Q64939313 | Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer's Disease Therapeutic Development. |
| Q26767289 | Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies |
| Q60044492 | Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model |
| Q38752201 | Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers |
| Q91583298 | Ginsenoside Rg1 Exerts Anti-inflammatory Effects via G Protein-Coupled Estrogen Receptor in Lipopolysaccharide-Induced Microglia Activation |
| Q49397357 | Glia maturation factor-β: a potential therapeutic target in neurodegeneration and neuroinflammation. |
| Q52593849 | Glial alterations in human prion diseases: A correlative study of astroglia, reactive microglia, protein deposition, and neuropathological lesions. |
| Q38819291 | Glial cells as drug targets: What does it take? |
| Q30313120 | Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients |
| Q52145262 | Gx-50 reduces β-amyloid-induced TNF-α, IL-1β, NO, and PGE2 expression and inhibits NF-κB signaling in a mouse model of Alzheimer's disease. |
| Q46561810 | HLA-A2 Alleles Mediate Alzheimer's Disease by Altering Hippocampal Volume |
| Q37199557 | HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. |
| Q55690891 | Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States. |
| Q47888806 | Heparan Sulfate Proteoglycans as Relays of Neuroinflammation. |
| Q49885816 | Hepcidin, an emerging and important player in brain iron homeostasis. |
| Q39034668 | High Dimensional Cytometry of Central Nervous System Leukocytes During Neuroinflammation |
| Q50182771 | High complement levels in astrocyte-derived exosomes of Alzheimer's disease. |
| Q48009605 | High-dimensional, single-cell characterization of the brain's immune compartment |
| Q39292060 | Hippocampal proteomics defines pathways associated with memory decline and resilience in normal aging and Alzheimer's disease mouse models |
| Q38902023 | Human IL-6, IL-17, IL-1β, and TNF-α differently regulate the expression of pro-inflammatory related genes, tissue factor, and swine leukocyte antigen class I in porcine aortic endothelial cells. |
| Q92238669 | Human Inner Ear Immune Activity: A Super-Resolution Immunohistochemistry Study |
| Q42374946 | Human TAUP301L overexpression results in TAU hyperphosphorylation without neurofibrillary tangles in adult zebrafish brain |
| Q40757303 | IFN-γ promotes τ phosphorylation without affecting mature tangles |
| Q54979990 | IL-1β suppresses cLTP-induced surface expression of GluA1 and actin polymerization via ceramide-mediated Src activation. |
| Q27315329 | IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. |
| Q58607667 | Ibuprofen prevents progression of ataxia telangiectasia symptoms in ATM-deficient mice |
| Q58773839 | IgM response against amyloid-beta in aging: a potential peripheral protective mechanism |
| Q26770766 | Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging |
| Q60950130 | Imaging and Molecular Mechanisms of Alzheimer's Disease: A Review |
| Q26766489 | Imaging of Leukocyte Trafficking in Alzheimer's Disease |
| Q89850629 | Immune and Inflammatory Determinants Underlying Alzheimer's Disease Pathology |
| Q38731476 | Immune-mediated processes in neurodegeneration: where do we stand? |
| Q38675216 | Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target? |
| Q89658608 | Impact of HMGB1, RAGE, and TLR4 in Alzheimer's Disease (AD): From Risk Factors to Therapeutic Targeting |
| Q47097794 | Impact of diabetes mellitus and chronic liver disease on the incidence of dementia and all-cause mortality among patients with dementia |
| Q92820179 | Impact of mesenchymal stem cell senescence on inflammaging |
| Q54941846 | Impacts of Acute Hypoxia on Alzheimer's Disease-Like Pathologies in APPswe/PS1dE9 Mice and Their Wild Type Littermates. |
| Q89659517 | Impaired Innate Immunity Mechanisms in the Brain of Alzheimer's Disease |
| Q47133736 | Impaired Resolution of Inflammation in Alzheimer's Disease: A Review |
| Q91129691 | Implications of sleep disturbance and inflammation for Alzheimer's disease dementia |
| Q31059488 | In Vivo Imaging of Human Neuroinflammation |
| Q38779574 | In vivo PET imaging of neuroinflammation in Alzheimer's disease. |
| Q36135752 | Increased Levels of Extracellular Microvesicle Markers and Decreased Levels of Endocytic/Exocytic Proteins in the Alzheimer's Disease Brain |
| Q33857828 | Increased White Matter Inflammation in Aging- and Alzheimer's Disease Brain |
| Q47150841 | Increased expression of Myc-interacting zinc finger protein 1 in APP/PS1 mice. |
| Q37628290 | Individual Patient Research (IPR) Outcomes with Alzheimer's Disease: The Psycho-neuro-immune Viewpoint |
| Q26749360 | Induced pluripotent stem cells in Alzheimer's disease: applications for disease modeling and cell-replacement therapy |
| Q55017301 | Infection of Fungi and Bacteria in Brain Tissue From Elderly Persons and Patients With Alzheimer's Disease. |
| Q90333330 | Inferring the Molecular Mechanisms of Noncoding Alzheimer's Disease-Associated Genetic Variants |
| Q34547897 | Inflammasomes as therapeutic targets for Alzheimer's disease |
| Q95856653 | Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development |
| Q41448365 | Inflammation and bone mineral density: A Mendelian randomization study. |
| Q88248784 | Inflammation-induced iron transport and metabolism by brain microglia |
| Q47634569 | Inflammatory pathology markers (activated microglia and reactive astrocytes) in early and late onset Alzheimer disease: a post mortem study |
| Q47968289 | Influence of Flaxseed Lignan Supplementation to Older Adults on Biochemical and Functional Outcome Measures of Inflammation. |
| Q89786611 | Influenza vaccination in early Alzheimer's disease rescues amyloidosis and ameliorates cognitive deficits in APP/PS1 mice by inhibiting regulatory T cells |
| Q55613035 | Inhaled Xenon Washout as a Biomarker of Alzheimer's Disease. |
| Q41186266 | Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor α Biochemical Pathway Can Lead to Favorable Outcomes in Alzheimer Disease |
| Q92711503 | Innate Immune Cells: Monocytes, Monocyte-Derived Macrophages and Microglia as Therapeutic Targets for Alzheimer's Disease and Multiple Sclerosis |
| Q60920839 | Innate Immunity Cells and the Neurovascular Unit |
| Q55289589 | Innate immune activation in Alzheimer’s disease. |
| Q49611026 | Innate immunity and inflammation in Alzheimer´s disease pathogenesis. |
| Q90266297 | Integration of Machine Learning Methods to Dissect Genetically Imputed Transcriptomic Profiles in Alzheimer's Disease |
| Q89461791 | Interleukin-12/23 deficiency differentially affects pathology in male and female Alzheimer's disease-like mice |
| Q39076924 | Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice. |
| Q64096969 | Interleukin-6 and lipoprotein-associated phospholipase A2 are associated with functional trajectories |
| Q59132127 | Interplay Between the Unfolded Protein Response and Immune Function in the Development of Neurodegenerative Diseases |
| Q48103278 | Intracellular tracing of amyloid vaccines through direct fluorescent labelling |
| Q47216965 | Iridoids and Other Monoterpenes in the Alzheimer's Brain: Recent Development and Future Prospects |
| Q59812412 | Is Alzheimer's Also a Stem Cell Disease? - The Zebrafish Perspective |
| Q38938961 | Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal |
| Q92800212 | Is Innate Memory a Double-Edge Sword in Alzheimer's Disease? A Reappraisal of New Concepts and Old Data |
| Q61799972 | Iso-α-acids, Hop-Derived Bitter Components of Beer, Attenuate Age-Related Inflammation and Cognitive Decline |
| Q55250888 | Krüppel-Like Factors in Metabolic Homeostasis and Cardiometabolic Disease. |
| Q50225528 | Kynurenine Pathway Metabolites in Alzheimer's Disease. |
| Q48505307 | LED enhances anti-inflammatory effect of luteolin (3',4',5,7-tetrahydroxyflavone) in vitro. |
| Q42987209 | La Deletion from Mouse Brain Alters Pre-tRNA Metabolism and Accumulation of Pre-5.8S rRNA, with Neuron Death and Reactive Astrocytosis. |
| Q42144867 | Lamotrigine Reduces Inflammatory Response and Ameliorates Executive Function Deterioration in an Alzheimer's-Like Mouse Model. |
| Q57810953 | Large-scale genome-wide enrichment analyses identify new trait-associated genes and pathways across 31 human phenotypes |
| Q46926746 | Let's make microglia great again in neurodegenerative disorders. |
| Q39159035 | Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. |
| Q90326185 | Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation |
| Q50586411 | Lifestyle and Neurocognition in Older Adults With Cardiovascular Risk Factors and Cognitive Impairment. |
| Q64990193 | Lipopolysaccharide-Induced Neuroinflammation as a Bridge to Understand Neurodegeneration. |
| Q91727697 | Longitudinal Changes in Regional Cerebral Perfusion and Cognition After Cardiac Operation |
| Q48369273 | Longitudinal In Vivo Imaging of the Cerebrovasculature: Relevance to CNS Diseases. |
| Q55380454 | Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice. |
| Q47926820 | Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia. |
| Q54986341 | Macrophage inflammatory factors promote epithelial-mesenchymal transition in breast cancer. |
| Q92266717 | Macrophages at CNS interfaces: ontogeny and function in health and disease |
| Q97884460 | Magnolol Ameliorates Behavioral Impairments and Neuropathology in a Transgenic Mouse Model of Alzheimer's Disease |
| Q92309827 | Manganese promotes the aggregation and prion-like cell-to-cell exosomal transmission of α-synuclein |
| Q41622815 | Manual Acupuncture Suppresses the Expression of Proinflammatory Proteins Associated with the NLRP3 Inflammasome in the Hippocampus of SAMP8 Mice |
| Q47839893 | Mass cytometry analysis of immune cells in the brain |
| Q36198218 | Mathematical model on Alzheimer's disease |
| Q47870999 | Melatonin protects against Aβ-induced neurotoxicity in primary neurons via miR-132/PTEN/AKT/FOXO3a pathway. |
| Q60303872 | Meta-analysis of Alzheimer’s disease on 9,751 samples from Norway and IGAP study identifies four risk loci |
| Q90079761 | Meta-analysis of human prefrontal cortex reveals activation of GFAP and decline of synaptic transmission in the aging brain |
| Q92620152 | Metabolic Endotoxemia: A Potential Underlying Mechanism of the Relationship between Dietary Fat Intake and Risk for Cognitive Impairments in Humans? |
| Q55425209 | Metabolic Risk Factors of Alzheimer's Disease, Dementia with Lewy Bodies, and Normal Elderly: A Population-Based Study. |
| Q38877855 | Metabolic network failures in Alzheimer's disease: A biochemical road map. |
| Q36100673 | Metabolic profiling distinguishes three subtypes of Alzheimer's disease |
| Q89498986 | Methotrexate causes persistent deficits in memory and executive function in a juvenile animal model |
| Q92994436 | MicroRNA-181a protects against pericyte apoptosis via directly targeting FOXO1: implication for ameliorated cognitive deficits in APP/PS1 mice |
| Q92089602 | Microenvironment Remodeling Micelles for Alzheimer's Disease Therapy by Early Modulation of Activated Microglia |
| Q92649247 | Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APPswe/PS1ΔE9 Transgenic Mice |
| Q38814802 | Microglia across the lifespan: from origin to function in brain development, plasticity and cognition |
| Q28074099 | Microglia communication: Parallels between aging and Alzheimer's disease |
| Q91137024 | Microglia heterogeneity along a spatio-temporal axis: More questions than answers |
| Q55073016 | Microglia in Alzheimer's Disease: Activated, Dysfunctional or Degenerative. |
| Q90671281 | Microglia in Pain: Detrimental and Protective Roles in Pathogenesis and Resolution of Pain |
| Q57153215 | Microglia prevent peripheral immune cell invasion and promote an anti-inflammatory environment in the brain of APP-PS1 transgenic mice |
| Q48137631 | Microglia turnover with aging and in an Alzheimer's model via long-term in vivo single-cell imaging. |
| Q42038294 | Microglia-Synapse Pathways: Promising Therapeutic Strategy for Alzheimer's Disease. |
| Q36413131 | Microglia-targeted stem cell therapies for Alzheimer disease: A preclinical data review |
| Q90049859 | Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development |
| Q47805553 | Microglial Function during Glucose Deprivation: Inflammatory and Neuropsychiatric Implications |
| Q26739495 | Microglial Priming and Alzheimer's Disease: A Possible Role for (Early) Immune Challenges and Epigenetics? |
| Q47899668 | Microglial modulation of neuronal activity in the healthy brain |
| Q38815779 | Microglial phenotypes in Parkinson's disease and animal models of the disease |
| Q55358469 | Microglial priming in Alzheimer's disease. |
| Q36812046 | Microglial priming through the lung-brain axis: the role of air pollution-induced circulating factors. |
| Q98727149 | Mito-Omics and immune function: Applying novel mitochondrial omic techniques to the context of the aging immune system |
| Q92483746 | Modeling Alzheimer's disease with iPSC-derived brain cells |
| Q92000754 | Modeling and Targeting Alzheimer's Disease With Organoids |
| Q47844178 | Modelling Neurodegenerative Microenvironment Using Cortical Organoids Derived from Human Stem Cells |
| Q47140966 | Modulating Neuroinflammation to Treat Neuropsychiatric Disorders |
| Q36364053 | Molecular Imaging of Neuroinflammation in Neurodegenerative Dementias: The Role of In Vivo PET Imaging |
| Q36661061 | Molecular Mechanisms Regulating LPS-Induced Inflammation in the Brain. |
| Q60954959 | Molecular Mechanisms of Synaptotoxicity and Neuroinflammation in Alzheimer's Disease |
| Q38840105 | Molecular Mechanisms of Vascular Dementia: What Can Be Learned from Animal Models of Chronic Cerebral Hypoperfusion? |
| Q64233563 | Molecular Network Analysis of the Urinary Proteome of Alzheimer's Disease Patients |
| Q55093166 | Molecular Pharmacology of Rosmarinic and Salvianolic Acids: Potential Seeds for Alzheimer's and Vascular Dementia Drugs. |
| Q26744105 | Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease |
| Q90266767 | Multicrossover Randomized Controlled Trial Designs in Alzheimer Disease |
| Q30276094 | Multifaceted interactions between adaptive immunity and the central nervous system |
| Q47950553 | Multiple Sclerosis: Implications of Obesity in Neuroinflammation |
| Q92479151 | Myeloid Cell and Transcriptome Signatures Associated With Inflammation Resolution in a Model of Self-Limiting Acute Brain Inflammation |
| Q39388337 | Myeloid Cells in the Central Nervous System |
| Q26770676 | Myeloid Dendritic Cells are Potential Players in Human Neurodegenerative Diseases |
| Q37675611 | NETosis in Alzheimer's Disease. |
| Q41051558 | Nanoplasmonic fiber tip probe detects significant reduction of intracellular Alzheimer's disease-related oligomers by curcumin |
| Q63246147 | Neonatal infection leads to increased susceptibility to Aβ oligomer-induced brain inflammation, synapse loss and cognitive impairment in mice |
| Q99579302 | Network Pharmacology Analysis and Molecular Characterization of the Herbal Medicine Formulation Qi-Fu-Yin for the Inhibition of the Neuroinflammatory Biomarker iNOS in Microglial BV-2 Cells: Implication for the Treatment of Alzheimer's Disease |
| Q38796950 | Network abnormalities and interneuron dysfunction in Alzheimer disease |
| Q58797942 | Network analysis of inflammatory responses to sepsis by neutrophils and peripheral blood mononuclear cells |
| Q26738352 | Neural stem/progenitor cells in Alzheimer's disease |
| Q93079510 | Neurodegeneration and Neuro-Regeneration-Alzheimer's Disease and Stem Cell Therapy |
| Q54978806 | Neuroimmflammation and microglia in glaucoma: time for a paradigm shift. |
| Q28079115 | Neuroimmune mechanisms in Krabbe's disease |
| Q92000951 | Neuroinflammation and Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance |
| Q92659576 | Neuroinflammation-Associated Aspecific Manipulation of Mouse Predator Fear by Toxoplasma gondii |
| Q98564963 | Neuronal regulation of immunity: why, how and where? |
| Q58773068 | Neuroprotective Activity of Sitagliptin via Reduction of Neuroinflammation beyond the Incretin Effect: Focus on Alzheimer's Disease |
| Q48497433 | Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model. |
| Q33602850 | Neurotoxic reactive astrocytes are induced by activated microglia |
| Q89460111 | Neurovascular unit dysregulation, white matter disease, and executive dysfunction: the shared triad of vascular cognitive impairment and Alzheimer disease |
| Q38688856 | Neutrophils Induce Astroglial Differentiation and Migration of Human Neural Stem Cells via C1q and C3a Synthesis. |
| Q39175804 | Neutrophils as protagonists and targets in chronic inflammation. |
| Q26771804 | New Drugs from Marine Organisms in Alzheimer's Disease |
| Q89207621 | New role of P2X7 receptor in an Alzheimer's disease mouse model |
| Q99238404 | Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer's Disease |
| Q37554157 | Nitric Oxide: Exploring the Contextual Link with Alzheimer's Disease |
| Q47396517 | Novel mechanisms and functions of complement. |
| Q37615654 | Obesity and neuroinflammatory phenotype in mice lacking endothelial megalin. |
| Q41273323 | Of Mice and Men: Comparative Analysis of Neuro-Inflammatory Mechanisms in Human and Mouse Using Cause-and-Effect Models |
| Q36301505 | Oleocanthal enhances amyloid-β clearance from the brains of TgSwDI mice and in vitro across a human blood-brain barrier model |
| Q50138399 | Oleocanthal-rich extra-virgin olive oil enhances donepezil effect by reducing amyloid-β load and related toxicity in a mouse model of Alzheimer's disease. |
| Q26769864 | Olive Oil and the Hallmarks of Aging |
| Q35765830 | On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death |
| Q37736146 | Opening up the DNA methylome of dementia |
| Q30238775 | Overview of Traumatic Brain Injury: An Immunological Context |
| Q93155837 | Oxylipin Profiling of Alzheimer's Disease in Nondiabetic and Type 2 Diabetic Elderly |
| Q50068373 | Ozone exposure effect on systemic prostaglandin F2α in rat plasma and urine may not reveal pulmonary damage through inflammation. |
| Q124094891 | PSA-NCAM Regulatory Gene Expression Changes in the Alzheimer’s Disease Entorhinal Cortex Revealed with Multiplexed in situ Hybridization |
| Q58608796 | Palm Fruit Bioactives modulate human astrocyte activity in vitro altering the cytokine secretome reducing levels of TNFα, RANTES and IP-10 |
| Q88651396 | Pathogenesis of Alzheimer's Disease Examined Using a Modified Puri-Li Model that Incorporates Calcium Ion Homeostasis |
| Q92854080 | Patterns of Expression of Purinergic Receptor P2RY12, a Putative Marker for Non-Activated Microglia, in Aged and Alzheimer's Disease Brains |
| Q39354673 | Peptidylarginine Deiminases-Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release? |
| Q47607906 | PerSubs: A Graph-Based Algorithm for the Identification of Perturbed Subpathways Caused by Complex Diseases |
| Q38820131 | Peripheral Tumor Necrosis Factor-Alpha (TNF-α) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD/TNF Transgenic Mice |
| Q57039635 | Peripheral immune system in aging and Alzheimer's disease |
| Q47739408 | Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair |
| Q39192238 | Personalized genetics of the cholinergic blockade of neuroinflammation. |
| Q47361647 | Phagocytic clearance of presynaptic dystrophies by reactive astrocytes in Alzheimer's disease |
| Q33679220 | Pharmacological Modulation of Functional Phenotypes of Microglia in Neurodegenerative Diseases |
| Q48093692 | Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases |
| Q52680159 | Plaque-dependent morphological and electrophysiological heterogeneity of microglia in an Alzheimer's disease mouse model. |
| Q93051104 | Positive Allosteric Modulation of Alpha7 Nicotinic Acetylcholine Receptors Transiently Improves Memory but Aggravates Inflammation in LPS-Treated Mice |
| Q38831521 | Posttranslational modification impact on the mechanism by which amyloid-β induces synaptic dysfunction. |
| Q38917772 | Potassium channel expression and function in microglia: Plasticity and possible species variations |
| Q41099377 | Potential Roles of Exosomal MicroRNAs as Diagnostic Biomarkers and Therapeutic Application in Alzheimer's Disease |
| Q39084950 | Potential importance of B cells in aging and aging-associated neurodegenerative diseases |
| Q39142379 | Prenylated Xanthones from the Roots of Cudrania tricuspidata as Inhibitors of Lipopolysaccharide-Stimulated Nitric Oxide Production. |
| Q64912462 | Preventive Effects of Dairy Products on Dementia and the Underlying Mechanisms. |
| Q64087524 | Processing of Mutant β-Amyloid Precursor Protein and the Clinicopathological Features of Familial Alzheimer's Disease |
| Q47120805 | Prostaglandin I2 is responsible for ameliorating prostaglandin E2 stress in stimulating the expression of tumor necrosis factor α in a β-amyloid protein -dependent mechanism |
| Q36574214 | Prostaglandin I₂ Attenuates Prostaglandin E₂-Stimulated Expression of Interferon γ in a β-Amyloid Protein- and NF-κB-Dependent Mechanism |
| Q34508284 | Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration |
| Q49918651 | Protective Effect of Human Leukocyte Antigen (HLA) Allele DRB1*13:02 on Age-Related Brain Gray Matter Volume Reduction in Healthy Women. |
| Q36713555 | Protein Arginine Methylation and Citrullination in Epigenetic Regulation |
| Q37614594 | Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimer's Therapy? |
| Q37697832 | Protein misfolding in neurodegenerative diseases: implications and strategies |
| Q52662413 | Proteomic analysis of plasma from rheumatoid arthritis patients with mild cognitive impairment. |
| Q37650729 | Protocol for a 24-Week Randomized Controlled Study of Once-Daily Oral Dose of Flax Lignan to Healthy Older Adults. |
| Q41613567 | Proximate Mediators of Microvascular Dysfunction at the Blood-Brain Barrier: Neuroinflammatory Pathways to Neurodegeneration |
| Q98176768 | Psychiatric face of COVID-19 |
| Q36844881 | Purinergic receptors as potential therapeutic targets in Alzheimer's disease |
| Q64099249 | Quantification of white matter cellularity and damage in preclinical and early symptomatic Alzheimer's disease |
| Q30371534 | REAC technology modifies pathological neuroinflammation and motor behaviour in an Alzheimer's disease mouse model |
| Q36774123 | RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers. |
| Q47732929 | Rat brain glucose transporter-2, insulin receptor and glial expression are acute targets of intracerebroventricular streptozotocin: risk factors for sporadic Alzheimer's disease? |
| Q28071816 | Rat models of spinal cord injury: from pathology to potential therapies |
| Q92803555 | Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology |
| Q48000590 | Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease |
| Q52603658 | Recent Advances: Decoding Alzheimer's Disease With Stem Cells. |
| Q27317159 | Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells |
| Q61814310 | Relationship Between Alzheimer's Disease and the Immune System: A Meta-Analysis of Differentially Expressed Genes |
| Q38694251 | Resilience dysregulation in major depressive disorder: focus on glutamatergic imbalance and microglial activation |
| Q37619977 | Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy |
| Q26747410 | Resolution of Inflammation: What Controls Its Onset? |
| Q38708742 | Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes. |
| Q38904336 | Review: Astrocytes in Alzheimer's disease and other age-associated dementias: a supporting player with a central role. |
| Q47305410 | Rheumatic diseases are associated with a higher risk of dementia: A nation-wide, population-based, case-control study |
| Q42373862 | Rheumatoid arthritis and risk for Alzheimer's disease: a systematic review and meta-analysis and a Mendelian Randomization study |
| Q47104106 | Rhinacanthin C Alleviates Amyloid-β Fibrils' Toxicity on Neurons and Attenuates Neuroinflammation Triggered by LPS, Amyloid-β, and Interferon-γ in Glial Cells |
| Q89621161 | Role of Host and Pathogen-Derived MicroRNAs in Immune Regulation During Infectious and Inflammatory Diseases |
| Q37542677 | Role of Mitochondria-Associated Endoplasmic Reticulum Membrane in Inflammation-Mediated Metabolic Diseases |
| Q26766462 | Role of docosahexaenoic acid in the modulation of glial cells in Alzheimer's disease |
| Q42376572 | Role of microglial amylin receptors in mediating beta amyloid (Aβ)-induced inflammation |
| Q99414286 | Roles of Specialized Pro-Resolving Lipid Mediators in Autophagy and Inflammation |
| Q96170632 | Rubus chingii Hu: an overview of botany, traditional uses, phytochemistry, and pharmacology |
| Q48034311 | Search for Alzheimer's disease biomarkers in blood cells: hypotheses-driven approach |
| Q63345230 | Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer's pathology |
| Q37716145 | Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer's Disease |
| Q47579436 | Sex differences in the phagocytic and migratory activity of microglia and their impairment by palmitic acid |
| Q43462638 | Shedding of membrane-associated LDL receptor-related protein-1 from microglia amplifies and sustains neuroinflammation |
| Q41158349 | Significance of long chain polyunsaturated fatty acids in human health. |
| Q87970835 | Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models |
| Q36954949 | Single-cell whole genome sequencing reveals no evidence for common aneuploidy in normal and Alzheimer's disease neurons |
| Q92772563 | Sleep and circadian rhythm disruption and stress intersect in Alzheimer's disease |
| Q91754985 | Sleep and inflammation: partners in sickness and in health |
| Q35890272 | Social-Biological Interactions in Oral Disease: A 'Cells to Society' View |
| Q37410147 | Soluble phospho-tau from Alzheimer's disease hippocampus drives microglial degeneration |
| Q91819996 | Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy |
| Q57190087 | Stem cell factor induces polarization of microglia to the neuroprotective phenotype |
| Q87932936 | Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System |
| Q92511851 | Suppression of Alzheimer's Disease-Like Pathology Progression by Mitochondria-Targeted Antioxidant SkQ1: A Transcriptome Profiling Study |
| Q37460856 | Surface area-dependence of gas-particle interactions influences pulmonary and neuroinflammatory outcomes. |
| Q59145861 | Synthesis of Ibuprofen Conjugated Molecular Transporter Capable of Enhanced Brain Penetration |
| Q38662596 | Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer's disease |
| Q37672845 | T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer's Disease: Potential Pools of New Biomarkers |
| Q39110320 | T cell responses in the central nervous system |
| Q90320717 | TLR4 (toll-like receptor 4) activation suppresses autophagy through inhibition of FOXO3 and impairs phagocytic capacity of microglia |
| Q38845677 | TMEM119 marks a subset of microglia in the human brain |
| Q51743108 | TNF alpha inhibitors in Alzheimer's disease: A systematic review. |
| Q91895181 | TNF-α promotes human antibody-mediated complement-dependent cytotoxicity of porcine endothelial cells through downregulating P38-mediated Occludin expression |
| Q52331413 | TNFα and IL-1β but not IL-18 Suppresses Hippocampal Long-Term Potentiation Directly at the Synapse. |
| Q26785919 | TREM2 in CNS homeostasis and neurodegenerative disease |
| Q48419551 | Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease. |
| Q26744219 | Targeting innate immunity for neurodegenerative disorders of the central nervous system |
| Q89011157 | Tau Activates Transposable Elements in Alzheimer's Disease |
| Q88588446 | Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo |
| Q90612341 | Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer's Disease |
| Q42252166 | Temporal Tracking of Microglia Activation in Neurodegeneration at Single-Cell Resolution |
| Q91706874 | Th17 and Cognitive Impairment: Possible Mechanisms of Action |
| Q94452114 | The Amyloid-beta rich CNS environment alters myeloid cell functionality independent of their origin |
| Q58486506 | The Amyloid-β Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions |
| Q58122158 | The Dual Role of Hepcidin in Brain Iron Load and Inflammation |
| Q39217126 | The Gut Microbiota and Alzheimer's Disease |
| Q58757545 | The Gut-Brain Axis in Alzheimer's Disease and Omega-3. A Critical Overview of Clinical Trials |
| Q96304563 | The Human Body as a Super Network: Digital Methods to Analyze the Propagation of Aging |
| Q39324087 | The IL-1β phenomena in neuroinflammatory diseases |
| Q90552914 | The Involvement of NLRP3 on the Effects of Minocycline in an AD-Like Pathology Induced by β-Amyloid Oligomers Administered to Mice |
| Q38671719 | The Lipoxygenases: Their Regulation and Implication in Alzheimer's Disease. |
| Q52147741 | The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease. |
| Q41334102 | The P2X7 Receptor Primes IL-1β and the NLRP3 Inflammasome in Astrocytes Exposed to Mechanical Strain |
| Q42006096 | The Rag-Ragulator Complex Regulates Lysosome Function and Phagocytic Flux in Microglia |
| Q55381143 | The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review. |
| Q99711183 | The Role of Microglia in Perioperative Neurocognitive Disorders |
| Q38676359 | The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases |
| Q63740571 | The Use of Pluripotent Stem Cell-Derived Organoids to Study Extracellular Matrix Development during Neural Degeneration |
| Q47550084 | The association of high sensitivity C-reactive protein and incident Alzheimer disease in patients 60 years and older: The HUNT study, Norway |
| Q30239749 | The blood brain barrier in Alzheimer's disease. |
| Q47122756 | The cargo protein MAP17 (PDZK1IP1) regulates the immune microenvironment |
| Q38562255 | The complex contribution of chemokines to neuroinflammation: switching from beneficial to detrimental effects |
| Q64989086 | The emerging risk of exposure to air pollution on cognitive decline and Alzheimer's disease - Evidence from epidemiological and animal studies. |
| Q61772849 | The identity and function of microglia in neurodegeneration |
| Q37085168 | The mixed-lineage kinase 3 inhibitor URMC-099 facilitates microglial amyloid-β degradation |
| Q37054759 | The relationship between complement factor C3, APOE ε4, amyloid and tau in Alzheimer's disease |
| Q40080281 | The role of the immunoproteasome in interferon-γ-mediated microglial activation |
| Q42656274 | The roles of inflammation and immune mechanisms in Alzheimer's disease |
| Q50532647 | The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer's disease. |
| Q64269112 | Theaflavins Improve Memory Impairment and Depression-Like Behavior by Regulating Microglial Activation |
| Q42135978 | Therapeutic effect of frankincense in a rat model of Alzheimer's disease |
| Q52371823 | Thioredoxin-Interacting Protein (TXNIP) in Cerebrovascular and Neurodegenerative Diseases: Regulation and Implication. |
| Q41876717 | Three-way interaction model to trace the mechanisms involved in Alzheimer's disease transgenic mice |
| Q64236740 | Thrombin and the in Neurotrauma, ALS, and Other Neurodegenerative Disorders |
| Q48182680 | Towards a Novel Class of Multitarget-Directed Ligands: Dual P2X7-NMDA Receptor Antagonists |
| Q60950945 | Traditional Japanese Herbal Medicine Yokukansan Targets Distinct but Overlapping Mechanisms in Aged Mice and in the 5xFAD Mouse Model of Alzheimer's Disease |
| Q90709364 | Transcriptional and Epigenetic Regulation of Microglia in Health and Disease |
| Q63246569 | Transcriptional mechanism of IRF8 and PU.1 governs microglial activation in neurodegenerative condition |
| Q91875027 | Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation |
| Q33635637 | Transcriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis |
| Q90262416 | Transcriptomic analysis reveals new hippocampal gene networks induced by prolactin |
| Q97644250 | Translocator Protein 18 kDa (TSPO) Deficiency Inhibits Microglial Activation and Impairs Mitochondrial Function |
| Q39547833 | Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis |
| Q47741254 | Trigonelline insulates against oxidative stress, proinflammatory cytokines and restores BDNF levels in lipopolysaccharide induced cognitive impairment in adult mice |
| Q90383670 | Type 1 Interleukin-4 Signaling Obliterates Mouse Astroglia in vivo but Not in vitro |
| Q52328598 | U1 snRNP Alteration and Neuronal Cell Cycle Reentry in Alzheimer Disease. |
| Q47751388 | Understanding AMD by analogy: systematic review of lipid-related common pathogenic mechanisms in AMD, AD, AS and GN. |
| Q48863961 | Understanding the Role of miR-33 in Brain Lipid Metabolism: Implications for Alzheimer's Disease. |
| Q47431150 | Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease. |
| Q54944394 | Unique and shared inflammatory profiles of human brain endothelia and pericytes. |
| Q52314225 | Unraveling the Complex Interplay Between T Cell Metabolism and Function. |
| Q48183122 | Validating GWAS Variants from Microglial Genes Implicated in Alzheimer's Disease |
| Q23915139 | Vascular-directed responses of microglia produced by methamphetamine exposure: indirect evidence that microglia are involved in vascular repair? |
| Q57039750 | Visceral fat-related systemic inflammation and the adolescent brain: a mediating role of circulating glycerophosphocholines |
| Q92603728 | Vitamin E and Alzheimer's disease: what do we know so far? |
| Q42656222 | Vitamin E family: Role in the pathogenesis and treatment of Alzheimer's disease |
| Q33705067 | Voluntary Exercise Promotes Glymphatic Clearance of Amyloid Beta and Reduces the Activation of Astrocytes and Microglia in Aged Mice |
| Q55318125 | Von Willebrand factor and ADAMTS13 activity in relation to risk of dementia: a population-based study. |
| Q47268030 | Water Quality and Brain Function |
| Q92819641 | White matter inflammation and cognitive function in a co-morbid metabolic syndrome and prodromal Alzheimer's disease rat model |
| Q46302841 | Why are Functional Amyloids Non-Toxic in Humans? |
| Q92021885 | Why microglia kill neurons after neural disorders? The friendly fire hypothesis |
| Q36285113 | Wine Flavonoids in Health and Disease Prevention |
| Q33784904 | YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies |
| Q89014037 | [18F]FEPPA a TSPO Radioligand: Optimized Radiosynthesis and Evaluation as a PET Radiotracer for Brain Inflammation in a Peripheral LPS-Injected Mouse Model |
| Q92486776 | [Efficacy and safety of metformin for Behcet's disease and its effect on Treg/Th17 balance: a single-blinded, before-after study] |
| Q42910436 | iRhoms in the brain - a new frontier? |
| Q55338776 | modCHIMERA: a novel murine closed-head model of moderate traumatic brain injury. |
| Q47757183 | γ-Secretase in microglia - implications for neurodegeneration and neuroinflammation. |
Search more.